MktsMarkets

AN2 Therapeutics, Inc.
NASDAQ: ANTXKey statistics
ANTX News
Stories mentioning ANTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 6,743 | 6,879 | 7,000 | 3,200 | 7,690 | 5,397 | 8,287 | 12,149 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 10,551 | 9,316 | 10,040 | 7,216 | 11,537 | 8,598 | 14,014 | 15,880 |
| Operating Income (Loss) | (10,551) | (9,316) | (10,040) | (7,216) | (11,537) | (8,598) | (14,014) | (15,880) |
| Interest Income | 523.00 | 605.00 | 687.00 | 754.00 | 888.00 | 1,076 | 1,267 | 1,445 |
| Interest Expense | ||||||||
| Other Expense | (1,267) | 1,267 | 0.00 | |||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (10,028) | (8,710) | (9,353) | (6,462) | (10,649) | (7,522) | (12,747) | (14,435) |
| Earnings Per Share (Basic) | (0.29) | (0.29) | (0.31) | (0.21) | (0.35) | (0.25) | (0.43) | (0.48) |
| Earnings Per Share (Diluted) | (0.29) | (0.29) | (0.31) | (0.21) | (0.35) | (0.25) | (0.43) | (0.48) |
| Weighted Average Shares Outstanding (Basic) | 34,060 | 30,216 | 30,276 | 30,172 | 30,054 | 29,828 | 29,841 | 29,825 |
| Weighted Average Shares Outstanding (Diluted) | 34,060 | 30,216 | 30,276 | 30,172 | 30,054 | 29,828 | 29,841 | 29,825 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ANTX
AN2 Therapeutics, Inc. (NASDAQ: ANTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol ANTX. It last traded at $5.02 (Nov 19, 2026, 9:36 AM ET), up 1.4% on the day. That gives AN2 Therapeutics a market capitalisation of $187.8M.
Over the past 52 weeks ANTX has traded between $1.00 and $7.19.
For the quarter ended Mar 31, 2026 it reported a net loss of $10.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$10.0M |
| Dec 31, 2025 | — | -$8.7M |
| Sep 30, 2025 | — | -$9.4M |
| Jun 30, 2025 | — | -$6.5M |
From AN2 Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…